医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Histogen Aesthetics Partners to Bring CellCeuticals to Asia

2014年10月09日 PM07:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Histogen Aesthetics, a company focused on the development of innovative skin care products utilizing regenerative medicine technology, announced today that it has entered a license and distribution agreement with JPGH Co., Ltd. (JPGH), to bring CellCeuticals Regenerative Skin Treatments to Greater Asia.

CellCeuticals Regenerative Skin Treatments (Photo: Business Wire)

CellCeuticals Regenerative Skin Treatments (Photo: Business Wire)

Behind JPGH are cross-border commercial pioneer, George Lee and John Paul Mitchell Systems (JPMS) co-Founder and Chairman and CEO, John Paul Dejoria. With more than three decades of global beauty industry experience, JPGH’s expansive network extends throughout Asia. Under this agreement, JPGH will target introducing the CellCeuticals skin care products line in Japan, Singapore, Indonesia, Malaysia, South Korea and Greater China (China, Taiwan, and Hong Kong).

CellCeuticals is a clinically-validated, premium line of skin care products based upon bioactive ingredients, such as proprietary growth factor lipopeptides, that have been shown to enhance skin rejuvenation and reverse the visible signs of aging. In clinical studies, significant improvements were demonstrated as early as two weeks, and a statistically significant reduction in total wrinkle area and depth was seen by week eight.

“With regions like Korea and Japan moving to the forefront of stem cell and regenerative medicine, Asia is primed for a sophisticated beauty line based on cellular science,” said George Lee, co-Founder and CEO of JPG Peace, Love and Happiness, Inc. and co-founder of JPGH. “Our experience and vast network tell us CellCeuticals is the right skin care line at the right time, and we believe it will be extremely well received.”

Histogen Aesthetics will also soon be bringing new innovation to the line through the addition of a unique regenerative medicine technology, working to improve skin aging at a cellular level.

“Regenerative medicine holds the promise of many advancements in both aesthetic and therapeutic treatments,” said Histogen investor John Paul Dejoria. “We are excited to partner with Histogen Aesthetics and to help deliver on these promises.”

JPGH Co., Ltd., was formed as a joint venture with regenerative medicine company Histogen, Inc., to bring next generation aesthetic products into the vast and growing Asian markets. In addition to JPMS, the largest privately-owned professional hair care company in the United States, Mr. Dejoria has founded both commercial and philanthropic organizations with large and impactful international presences. In addition to being an exclusive distributor of the Paul Mitchell hair care line in Korea, Mr. Lee has worked with a number of biomedical and technology companies, including partnering with NASA’s Jet Propulsion Laboratory throughout Asia. He is also actively involved in significant international relations projects, including co-founding the groundbreaking Korea Launch Hub with China.

“We are honored that the CellCeuticals technology, formulations and vision have been recognized by innovators of the beauty industry,” said Dr. Gail Naughton, CEO of Histogen, Inc. “It is truly exciting to be working with Mr. Lee and Mr. Dejoria, and their expansive network, to bring the line into Asia.”

The CellCeuticals system is made up of 11 distinctive products including the Extremely Gentle Skin Cleanser, CellGenesis Regenerative Skin Treatment, and PhotoDefense Color Radiance SPF55+ with proprietary and patented PhotoPlex technology. The line is currently available at retailers including QVC.com, Dermstore.com, and Nordstrom.com, as well as www.cellceuticalskincare.com.

About Histogen Aesthetics

Histogen Aesthetics LLC, formed in 2008 as a subsidiary of Histogen, Inc., focuses on the development of innovative skin care products utilizing regenerative medicine technology. Histogen Aesthetics’ technology is based on the expertise of founder Dr. Gail K. Naughton, in which fibroblasts are grown under unique conditions, producing a complex of naturally-secreted proteins and synergistic bio-products known to stimulate skin cells to regenerate and rejuvenate tissues. In 2014, Histogen Aesthetics acquired CellCeuticals Biomedical Skin Treatments, a line of scientifically-proven products that reactivate cells to help aging skin perform and look healthier and younger. For more information, visit www.cellceuticalskincare.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141009005136/en/

CONTACT

Histogen Aesthetics
Eileen Brandt, 858-200-9520
ebrandt@histogeninc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer